Question-and-Answer SessionWell, maybe just to start off, would you like to share some opening thoughts on Alnylam for those who are a little bit less familiar?Jeffrey PoultonCFO & Executive VP Sure. We're a company that pioneered a new class of medicine called RNAi therapeutics. It's been a 20-plus-year journey for the company. There was a lot of work, probably for the first 10-plus years around delivery. But once the company figured out delivery, there's really been a steady cadence of progress. And wher ...

Core Insights - Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery (AGD), which aims to accelerate drug discovery through clinical genomic data [1][2][3] - The AGD dataset will enhance Alnylam's ability to identify new therapeutic targets for RNA interference (RNAi) therapeutics, which work by silencing disease-causing genes [4][5] - The AGD now includes nine members, with Alnylam being the latest addition, and plans to expand its dataset by sequencing an additional 31,250 whole genomes, building on an existing cohort of 250,000 [3][5] Company and Industry Developments - The AGD is led by Illumina and Nashville Biosciences, focusing on leveraging genomic data to drive innovation in therapeutics [2][3] - Alnylam's participation is expected to strengthen the AGD's clinical genomic database, which aims to provide diverse and representative data for drug discovery [5][6] - The alliance has already identified novel therapeutic targets, particularly in autoimmune and neurodegenerative diseases, demonstrating the dataset's value to its members [6][8] Technological Advancements - The AGD utilizes advanced sequencing and data analysis technologies, such as DRAGEN and Illumina Connected Analytics, to enhance the accuracy and speed of genomic insights [6][8] - The alliance plans to incorporate multiomic layers into its dataset, which will facilitate faster target discovery and therapy development [8] - The AGD dataset aims to link diverse genomic data with clinical phenotyping to ensure that discoveries benefit a wide range of populations [5][6]

 Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics. "Collaborating with the leading innovator in RNAi therapeutics represents significant validation of our Cell-Seq platform's unique ability to connect cellular pathways to actionable drug targets," said Vin ...

Core Insights - Codexis, Inc. has appointed Cynthia Collins to its Board of Directors, bringing extensive experience in the pharmaceutical and biotech industry [1][2] - The company aims to expand its commercial footprint with its ECO Synthesis toolbox, which is positioned to unlock the potential of RNA-based therapeutics [2] Company Overview - Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, utilizing its proprietary CodeEvolver® technology platform [3] - The company is developing the ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route [3] - Codexis' unique enzymes are designed to improve yields, reduce energy usage and waste generation, and enhance efficiency in manufacturing [3] Leadership Background - Cynthia Collins has over four decades of experience in the pharmaceutical and biotech sectors, currently serving as Executive Chair and interim CEO of Nutcracker Therapeutics [2] - Her previous roles include CEO of Editas Medicine, where she oversaw the first clinical trial of an in vivo CRISPR gene editing therapy, and various leadership positions at GE Healthcare and Baxter Healthcare [2]